Filter
53
Text search:
pharma
company
Featured
Recommendations
2
New Publications
12
Language
Document type
No document type
21
Studies & Reports
18
Guidelines
7
Strategic & Response Plan
2
Fact sheets
2
Manuals
1
Situation Updates
1
Resource Platforms
1
Countries / Regions
Ethiopia
4
India
4
Kenya
4
Nigeria
3
Uganda
3
Global
3
Ghana
2
Sierra Leone
1
Philippines
1
Germany
1
Tanzania
1
South Africa
1
Bangladesh
1
Sudan
1
Ukraine
1
Authors & Publishers
Publication Years
Category
Countries
17
Pharmacy & Technologies
5
Public Health
3
Clinical Guidelines
3
Women & Child Health
3
Toolboxes
Pharmacy
10
HIV
5
AMR
5
COVID-19
4
Mental Health
3
Global Health Education
3
NTDs
3
NCDs
3
TB
2
Health Financing Toolbox
2
Rapid Response
1
Specific Hazards
1
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
22 Sept. 2021
The rapid development of effective Covid-19 vaccines in 2020 gave hope to the world in the darkest days of the deadly pandemic. However, the vaccine roll-out has been massively skewed towards wealthy nations. While rich states have hoarded vaccines, companies have also played a decisi
...
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covi
...
BUKO Pharma-Kampagne has investigated the causes and consequences of antibiotic resistance in India, South Africa, Tanzania and Germany. Together with our partners we collected data and did interviews with numerous stakeholders. The outcome is prese
...
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac
...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan
...
Irresponsible pharmaceutical companies fuel the proliferation of superbugs through supply chain pollution, the European Public Health Alliance (EPHA) reports. The advocacy group uncovered lapses such as dirty production and inadequate waste disposal in the production of antimicrobials in China and I
...
Global UNIDO Project: Strengthening the local production of essential medicines in least developed and developing countries
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
Development finance institutions owned by European governments and the World Bank Group are spending hundreds of millions of dollars on expensive for-profit hospitals in the Global South that block patients from getting care, or bankrupt them, with some even imprisoning patients who cannot afford th
...
Review over the work and challenges of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) in combatting counterfeiting of medicines in Nigeria.
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries as of April 2014. The focus is primarily on those
...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand
...
How to address the global crisis in antibiotic research and development.
The report includes a comprehensive summary and critical evaluation of recent initiatives to overcome the barriers to achieve sustainable access to antibiotics. As antibiotic resistance will continue to develop as long as we
...
Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa
recommended
The survey aimed at evaluating the quality of selected antimalarials in six countries of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic of Tanzania). These countries have been supported by WHO to strengthen their regulatory controls o
...
Key Features:
• Module Users: Disaster Management Trainers
• Training Targets: State Government and District
officials / Disaster Management Authorities / Disaster
Management Planners and Responders
• Training Duration: 5 working days (one week)
• Trainers Input: Multi-disciplinary
...
